Executive readout · one minute
What the filings say
- 10-Q report · filed Nov 6, 2026
- Allogene Therapeutics reported ALPHA3 interim results showing MRD negativity in 58.3% (7/12) of cema-cel patients versus 16.7% (2/12) under observation, with no treatment-related serious adverse events reported in the cema-cel arm.
The audio replay and transcript follow the call.